Vistagen Hits Key Safety Milestone for Social Anxiety Disorder Drug — Vistagen Therapeutics, Inc.

Event summary

Vistagen's fasedienol nasal spray program for social anxiety disorder meets ICH E1 safety exposure recommendations as of May 31, 2026.
Over 1,500 subjects received at least one exposure, with 300+ having 6-month exposure and 100+ with 12-month exposure.
Topline results from Phase 3 PALISADE-4 trial expected in Q2 2026, with Repeat Dose Study results in Q3 2026.
FDA Fast Track designation previously granted for fasedienol's acute treatment of social anxiety disorder.

The big picture

Vistagen's achievement of ICH E1 safety milestones positions fasedienol as a potential first-of-its-kind treatment for acute social anxiety, leveraging a unique nose-to-brain delivery mechanism. The company's progress comes amid growing demand for safer, rapid-onset anxiety treatments, though success will depend on securing regulatory alignment and demonstrating sustained efficacy in ongoing trials.

What we're watching

Regulatory Alignment: Whether Vistagen can secure FDA agreement on patient exposure requirements for NDA submission.
Clinical Efficacy: The impact of upcoming PALISADE-4 and Repeat Dose Study results on fasedienol's regulatory path.
Market Differentiation: How fasedienol's non-systemic mechanism of action will position it against existing anxiety treatments.